|
Market Cap (18-May) $95,239,352 (971st) |
Close (9-Dec) $1.04 |
Volume (9-Dec) 0 |
Shortsold (3-Dec) 50,000 (0.05%) (513th) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.144 |
BD1 released this announcement to the ASX on 16 April 2021, 14:38. The announcement is not marked as price sensitive, and is 14 page(s) in length and 317.51kb in size.
You can view all announcements from BD1 and see how they appear on a price chart on the announcements page.
At the date of this announcement, BD1 was 0.003% short sold according to ASIC data. It was ranked the 590th most shorted stock on the ASX. It is now ranked as the 513th most shorted stock on the ASX with 0.054% of total shares short sold as of the latest reported data (03 December 2021).
| Other Recent Announcements from BD1 | |
|---|---|
| BARD1 Changes its Name to INOVIQ | 8 December 2021, 8:58 |
| Cleansing Notice - Issued of Four Shares - Resolution 5 AGM | 7 December 2021, 12:12 |
| Application for quotation of securities - BD1 | 7 December 2021, 12:06 |
| Appendix 3G - Long Term Incentive Options Issued to CEO | 16 April 2021, 14:38 |
| BARD1 Signs Option Agreement for Type 3C Diabetes Test | 13 April 2021, 9:03 |
| Appendix 2A | 19 March 2021, 15:14 |
| Positive Results Evaluation of EXO-NET in Pancreatic Cancer | 16 March 2021, 8:32 |
You must be logged in to post a reply.
BARD1 Life Sciences 